Medicine and Dentistry
Patient
90%
Doxorubicin
45%
Combination Therapy
27%
Recommended Drug Dose
27%
Recurrent Ovarian Cancer
27%
Diseases
18%
Chemotherapy
18%
Neutropenia
18%
Irinotecan
18%
Drug Dose Reduction
18%
Therapeutic Procedure
18%
Adverse Event
9%
Toxicity
9%
Platinum
9%
Female Genital Tract Cancer
9%
Blood Toxicity
9%
Chemistry
Concentration
100%
Dose
90%
Doxorubicin
45%
Irinotecan
18%
Maximum Tolerated Dose
18%
Procedure
18%
Antitumor
9%
Platinum
9%
Taxane
9%
Hydrochloride
9%
Chemical Reaction
9%
Rate
9%
Safety
9%
Toxicity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
45%
Diseases
18%
Combination Therapy
18%
Neutropenia
18%
Maximum Tolerated Dose
18%
Irinotecan
18%
Toxicity
9%
Adverse Event
9%
Taxane
9%
Platinum
9%
Female Genital Tract Cancer
9%
Blood Toxicity
9%
Biochemistry, Genetics and Molecular Biology
Doxorubicin
45%
Dose
45%
Clinical Study
27%
Recommended Drug Dose
27%
Drug Dose Reduction
18%
Maximum Tolerated Dose
18%
Neuroscience
Doxorubicin
45%
Irinotecan
18%
Chemotherapy
9%
Chloride
9%
Taxane
9%